Real world evidence research breakfast seminar
We were delighted to attend and present a paper at the Tech Observer event in Singapore earlier this month
APAC Director Pei Li Teh, and Research Manager, Colin Tan, attended the event. Pei Li presented the paper ‘Inhale, exhale: How using real world data helped asthma patients breathe easier across Asia’. In her paper she demonstrated how published real world data research provided pharma companies with an in-depth understanding of asthma patients’ across Asia. The data provided the healthcare community with a tool to supply tailored communications supporting different patient types, instead of a ‘one size fits all’ approach.
Conducting research for publication
Pei Li Teh explains how real world insights provide an opportunity for brands to find, demonstrate and communicate their value to patients, healthcare and society.
Eyeforpharma Real World Evidence Conference Round up 2018
Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)
This year has seen a turning point for Japan's pharma industry, as the government and the industry encourage a rapid move towards increased use of RWE from April 2018. Real World Data (RWD) sources provide an unprecedented opportunity for companies to find, demonstrate and communicate their real value to patients, healthcare and society. The conference included topics addressing commercial and medical needs, allowing both communities to come together for the first time encouraging collaboration across functions.
Eyeforpharma – Real World Evidence 2018
16-17 May in Tokyo, Japan
Research Partnership is delighted to be attending the Eyeforpharma Real World Evidence (RWE) conference in Tokyo, Japan 16-17 May. RWE is currently a very hot topic for the Japanese pharma industry, with an increased push to place RWE as a strategic imperative for pharma.
Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
First there was Ebola and now there is Zika; two official World Health Organization (WHO) Public Health Emergencies of International Concern (PHEIC) within as many years. Whenever global health crises such as these emerge, the pharmaceutical industry comes under intense scrutiny for not having an immediate solution available. Part of the problem is that prevention is not always financially viable; the substantial R&D costs of developing vaccines or treatments for all known and potential threats that may or may not one day develop into global pandemics is not a feasible burden for the industry to carry alone.